Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial
Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial
复制标题
DOI：
10.1016/j.jad.2018.02.056
复制
发表时间：
2018-08-01
影响因子：
6.6
通讯作者：
Akhondzadeh, Shahin
中科院分区：
文献类型：
--
作者：
Arabzadeh, Somaye;Hakkikazazi, Elham;Akhondzadeh, Shahin
背景：重度抑郁症（MDD）给社会带来了沉重的健康和经济负担。 MDD 的传统药物疗法部分有效，并且对药物的反应通常会延迟一些。最近有报道称口服氯胺酮具有抗抑郁作用。方法：我们采用双盲对照试验来检验氯胺酮与常规服用舍曲林联合用药时的治疗效果的时间进程。共有 81 名患者参与了该研究，并在基线以及试验开始后 2、4 和 6 周时使用汉密尔顿抑郁评定量表（HDRS）进行评分。结果：一般线性模型重复测量显示时间 x 治疗相互作用对 HDRS 评分有显着影响，治疗后所有时间点都有显着差异。与安慰剂组 (42.5%) 相比，氯胺酮组 (85.4%) 的早期改善明显更大。我们没有观察到氯胺酮给药有任何副作用。局限性：我们的随访仅限于治疗开始后 6 周，无法揭示口服氯胺酮潜在的长期不良反应及其益处的可持续性。结论：总而言之，我们的结果表明，口服氯胺酮可被视为舍曲林缓解抑郁症状的合适佐剂。
Background: Major depressive disorder (MDD) exerts a high health and financial burden on society. The conventional pharmacotherapies for MDD are partially effective and the response to medication often starts with some delay. There are recent reports of antidepressant effects for oral ketamine.Methods: We employed a double-blind controlled trial to examine the time course of the therapeutic effect of ketamine when combined with the conventional administration of sertraline. A total of 81 patients participated in the study and were scored with the Hamilton Depression Rating Scale (HDRS) at baseline and at 2, 4 and 6 weeks after the start of the trialResults: General linear model repeated measures demonstrated significant effect for time x treatment interaction on the HDRS scores, with significant difference at all time points post treatment. Early improvement was significantly greater in the ketamine group (85.4%) compared to the placebo group (42.5%). We did not observe any side effects for ketamine administration. Limitations: Our follow up was limited to 6 weeks post initiation of treatment and cannot reveal the potential long-term adverse effects of oral ketamine and the sustainability of its benefit.Conclusion: Altogether, our results suggest that oral ketamine may be considered as suitable adjuvant to sertraline in relieving depressive symptoms.